Helicobacter Pylori Eradication Therapy for Epileptic Children

Status Completed

Clinical Trial Summary

Helicobacter pylori (H. pylori) infection is associated with several health problems. The role of H. pylori infection in epilepsy has been investigated in a few studies. To the best of our knowledge, there have been no previous studies on the effect of treating H. pylori infection on seizure frequency among children with drug-resistant idiopathic generalized epilepsy. This study aims to evaluate the effect of treating H. pylori infection on seizure frequency among children with drug-resistant idiopathic generalized epilepsy.

Clinical Trial Description

Helicobacter pylori (H. pylori) is a spiral-shaped Gram-negative bacterium, which causes chronic infection in more than 50% of human population. H. pylori infection is associated with several gastrointestinal disorders, such as gastritis and gastric/duodenal ulcers. Moreover, accumulating body of evidence indicates the possible role of H. Pylori infection in extraintestinal health problems, such as iron deficiency anemia, immune thrombocytopenic purpura (ITP), numerous dermatological diseases, Alzheimer disease, Parkinson's disease, multiple sclerosis, and epilepsy. Epilepsy is a common neurological disorder characterized by recurrent unprovoked seizures. This condition affects 0.5% to 1% of all children and is associated with neurobiological, cognitive, psychological, and social consequences. Seizures can usually be controlled by anti-epileptic drugs (AEDs) in up to two-thirds of children with epilepsy. However, this leaves a significant part of epileptic children whose seizures are not controlled by pharmacotherapy. The development of epilepsy is highly complex and can be attributed to multiple etiologies classified into structural (e.g., malformation, trauma, ischemia), genetic, infectious, metabolic, and immune factors. However, the etiology remains unknown in about half of epileptic children. Idiopathic generalized epilepsies (IGE) constitute about one-third of all epilepsies. Efforts to explore new possible mechanisms contributing to the development of epilepsy, particularly drug-resistant IGE, could contribute to the development of new therapeutic strategies to improve patients' outcomes. The role of H. pylori infection in epilepsy has been investigated in a few studies, some of which reported that the seroprevalence of H. pylori infection is significantly higher in patients with idiopathic epilepsy compared with patients with other chronic diseases, and that H. pylori infection is associated with poor prognosis. Potential H. pylori-induced epileptic effects are probably immune-mediated that can be attributed to a cross-mimicry mechanism between H. pylori and human cellular phospholipids with production of autoimmune antibodies (e.g., anti-cardiolipin) and H. pylori infection-related activation of pro-inflammatory cells with systemic release of proinflammatory cytokines (e.g., IL-6, 8 and TNF- α) which are involved in disruption of the blood-brain barrier and neuroinflammation. To the best of our knowledge, there have been no previous studies on the effect of treating H. pylori infection on seizure frequency among children with drug-resistant IGE. This study aims to evaluate the effect of treating H. pylori infection on seizure frequency among children with drug-resistant IGE. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05297695
Study type	Interventional
Source	Sohag University
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	April 20, 2022
Completion date	December 30, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05061732` - Helicobacter Pylori Eradication and Follow-up	Phase 4
Completed	`NCT03779074` - Comparing the Efficacy of Hybrid, High-dose Dual and Bismuth Quadruple Therapies	Phase 3
Completed	`NCT06076681` - A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules	Phase 1/Phase 2
Recruiting	`NCT05329636` - Auto Fecal Microbial Transplant Post Helicobacter Pylori Antibiotic Therapy	Phase 1/Phase 2
Recruiting	`NCT05065138` - Comparison of Helicobacter Pylori Eradication Effect Before and After Training of Gastroenterologists	N/A
Completed	`NCT05049902` - Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication	Phase 4
Not yet recruiting	`NCT06200779` - Tailored vs. Empirical Helicobacter Pylori Infection Treatment	Phase 4
Not yet recruiting	`NCT06037122` - Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication
Completed	`NCT04617613` - Comparing Different Regimens for Eradication of Helicobacter Pylori in Kuwait	Phase 4
Completed	`NCT02873247` - Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori
Withdrawn	`NCT02552641` - Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole	Phase 4
Completed	`NCT02557932` - Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication	Phase 3
Recruiting	`NCT02249546` - Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection	Phase 4
Completed	`NCT01933659` - Anti-H. Pylori Effect of Deep See Water	Phase 3
Unknown status	`NCT01464060` - 14-day Quadruple Hybrid vs. Concomitant Therapies for Helicobacter Pylori Eradication	Phase 4
Completed	`NCT00841490` - Oral H. Pylori Prevalence in Intellectually & Developmentally Disabled Adults	N/A
Recruiting	`NCT05549115` - Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection	N/A
Recruiting	`NCT05728424` - One vs Two Weeks Treatment for H.Pylori Eradication A RANDOMIZED NON-INFERIORITY PLACEBO CONTROLLED TRIAL	Phase 3
Recruiting	`NCT05997433` - Efficacy of 7-day Versus 14-day Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori（SHARE2302)	N/A
Completed	`NCT04708405` - The Relationship Between Helicobacter Pylori Infection and Inflammatory Bowel Diseases: A Real-life Observation